Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04781192
Title The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Kansas Medical Center
Indications

cholangiocarcinoma

gallbladder cancer

Therapies

Durvalumab + Regorafenib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Kansas Cancer Center - Overland Park Recruiting Overland Park Kansas 66210 United States Details
The University of Kansas Medical Center Recruiting Westwood Kansas 66205 United States Details
University of Kansas Cancer Center - North Recruiting Kansas City Missouri 64154 United States Details
University of Kansas Cancer Center - Lee's Summit Recruiting Lee's Summit Missouri 64064 United States Details
The University of Kansas Medical Center Recruiting North Kansas City Missouri 64116 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field